Elena Rossi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis.

Journal: Blood advances

Published: May 18, 2026

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

Journal: International journal of molecular sciences

Published: April 21, 2026

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.

Journal: ESMO real world data and digital oncology

Published: April 03, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies.

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies.

Journal: Hospital pharmacy

Published: February 23, 2026

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco-Hematology.

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco-Hematology.

Journal: International journal of laboratory hematology

Published: February 23, 2026

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy.

Journal: Therapeutic advances in hematology

Published: December 24, 2025

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.

Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.

Journal: Annals of hematology

Published: December 17, 2025

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: December 09, 2025

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Journal: Haematologica

Published: November 17, 2025

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.

Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy : Correction to: annals of hematology.

Journal: Annals of hematology

Published: November 12, 2025

Showing 1-12 of 126

Last Updated: 09/26/2026